advertisement-vertical Download Proto magazine app
Social Icons

An Ounce of Prevention

Five substances are being used or tested to keep prodromal symptoms from progressing into schizophrenia, but the risk-benefit ratios are still being worked out.


Chemical (Trade name): Olanzapine (Zyprexa)
Drug class: Atypical antipsychotic (distinguished from typical counterparts by a reduced tendency to cause neurological side effects)
Notable risks: Insulin resistance, weight gain, type 2 diabetes, elevated cholesterol
Possible benefits: Data suggests that this drug—the only antipsychotic tested in a prodromal clinical trial—produces a 2.5-fold decrease in the risk of psychotic conversion; however, the treatment group’s marginal sample size renders the results inconclusive.

Chemical (Trade name): Aripiprazole (Abilify)
Drug class: Atypical antipsychotic
Notable risks: Nausea, insomnia, restlessness
Possible benefits: Post-market surveillance of this drug, used in the PIER schizophrenia-prevention program, suggests a lower risk of metabolic side effects (including weight gain and diabetes) than that posed by olanzapine.

Chemical (Trade name): Ziprasidone (Geodon)
Drug class: Atypical antipsychotic
Notable risks: Slowed cardiac conduction, insomnia
Possible benefits: Poses less risk of metabolic side effects but has been known to cause weight loss. Prodromal clinical trial in planning stages.

Chemical (Trade name): D-serine
Drug class: Notable risks: Possible kidney damage (based on research in rats)
Possible benefits: May reverse the loss of synapses, a hallmark of schizophrenia. In Phase III trials with schizophrenia patients; clinical trials in prodromal patients in planning stages at three sites.

Chemical (Trade name): Omega-3 (fish oil)
Drug class: Fatty acid
Notable risks: Bleeding at high doses
Possible benefits: Like d-serine, may promote synaptic growth, though there’s conflicting evidence about benefits. One preliminary study detected none; more recent data, however, suggests that omega-3 significantly reduces risk of psychotic conversion.


Halting Schizophrenia

After symptoms begin but before reality departs, aggressive treatment may forestall the disease. But is the intervention worth the risks?

Protomag on Facebook Protomag on Twitter